![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1301035
¹Ì±¹ÀÇ ÇコÄɾî¿ë Á¦3ÀÚ¹°·ù ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : »ê¾÷º°, °ø±Þ üÀκ°, ¼ºñ½º À¯Çüº°, Áö¿ªº°, ºÎ¹®º° µ¿Çâ(2023-2030³â)U.S. Healthcare Third-party Logistics Market Size, Share & Trends Analysis Report By Industry (Biopharmaceutical, Pharmaceutical, Medical Device), By Supply Chain, By Service Type, By Region, And Segment Forecasts, 2023 - 2030 |
¹Ì±¹ ÇコÄɾî¿ë Á¦3ÀÚ¹°·ù(Healthcare Third-party Logistics) ½ÃÀå ±Ô¸ð´Â 2030³â 1,608¾ï ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù.
½ÃÀåÀº ÀǾàǰ, »ý¹°Á¦Á¦ ½ÃÀå ¹Ì±¹ ¿ìÀ§¼º, ´Ù¼ö ±â¾÷ Á¸Àç, ¹ÙÀÌ¿ÀÀǾàǰ ¼öÃâÀÔ Áõ°¡¿¡ ÀÇÇØ ¿¹Ãø ±â°£ µ¿¾È 9.04%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
COVID-19 ÆÒµ¥¹Í ¶§ ±¹³» COVID-19 ¹é½Å ¼ö¿ä°¡ ³ô¾Ò´ø °ÍÀº º´¿ø, °ø°ø±â°ü ¹× ±âŸ ±â°üÀÌ Á¦3ÀÚ ¹°·ù ¼ºñ½º Á¦°ø¾÷ü¿Í ÆÄÆ®³Ê½ÊÀ» ¸Î´Â ¿øÀÎÀÌ µÇ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î 2020³â ¿ÀÇÏÀÌ¿À ÁÖ º¸°Ç±¹Àº COVID-19 ¹é½Å À¯ÅëÀ» À§ÇØ Ä«µð³Î Çコ¿Í Á¦ÈÞÇß½À´Ï´Ù. ÀÌ·Î ÀÎÇØ À¯Çà±â°£ µ¿¾È µ¿±¹ Á¦3ÀÚ¹°·ù ¼ºñ½º ¼ö¿ä°¡ °³¼±µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
±¹³»´Â ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, ½Å°æÁúȯ µî Ä¡·á¸¦ ¸ñÀûÀ¸·Î ÇÑ ¹ÙÀÌ¿ÀÀǾàǰ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±¹³»´Â ÀǾàǰ¿¡ °üÇÑ ¿¬±¸°¡ ¸¹ÀÌ ÁøÇàµË´Ï´Ù. ÀÌ·¯ÇÑ ¸ðµç ¿äÀεéÀº Á¦3ÀÚ ¹°·ù ¼ºñ½º ¼ö¿ä¸¦ °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Áö³ 5³â°£ »ó´çÇÑ ¼öÀÇ ÀǾàǰ, ¹ÙÀÌ¿ÀÀǾàǰ, ÀÇ·á±â±â°¡ ±¹³» ½ÂÀÎ, ¹ß¸ÅµÇ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 1¿ù, ¾ÏÁ¨Àº Ȱµ¿¼º ´Ù°üÀýÇü û¼Ò³â Ư¹ß¼º °üÀý¿° Ä¡·áÁ¦·Î ¾ÏÁ¦ºñŸ ¹ÙÀÌ¿À½Ã¹Ð·¯¸¦ Ãâ½ÃÇß½À´Ï´Ù. À¯»çÇÏ°Ô 2022³â 12¿ù, USFDA´Â ´Ù¹ß¼º °æÈÁõ Ä¡·áÁ¦·Î¼ Briambi ublituximab-xiiy¸¦ ½ÂÀÎÇß½À´Ï´Ù. ¹Ì±¹ À¯»çÇÑ ÀǾàǰÀÌ ½ÂÀÎµÇ°í »ó½ÃµÊÀ¸·Î½á ¹Ì±¹ Á¦3ÀÚ ¹°·ù ¼ºñ½º ±âȸ°¡ âÃâµÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
°Ô´Ù°¡ ½ÃÀå ÁÖ¿ä »ç¾÷ü Àü·« ÀÌ´Ï¼ÅÆ¼ºê´Â ¾ÕÀ¸·Î ¼ö³â°£ ÀÌ Áö¿ª ½ÃÀå¿¡ ¼ºÀå ±âȸ¸¦ °¡Á®¿Ã °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 1¿ù, ¼¾½Ã³ÝÀº ÇコÄɾî Ÿ»ç ¸®½ºÅ© °ü¸®¸¦ °¡¼ÓÈÇϱâ À§ÇØ 900¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ̸ç, ÀÚ±ÝÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ ÀÚ±Ý Á¶´ÞÀº Ballad Ventures¿Í Rex Health Ventures¸¦ Æ÷ÇÔÇÑ MemorialCare Innovation Fund°¡ ÁÖµµÇÑ °ÍÀ¸·Î, ÀÚ±Ý Á¶´Þ ÃѾ×Àº 2,200¸¸ ´Þ·¯¸¦ ÃʰúÇß½À´Ï´Ù.
¹Ì±¹ ÇコÄɾî¿ë Á¦3ÀÚ¹°·ù ½ÃÀå ÇÏÀ̶óÀÌÆ®
The U.S. healthcare third-party logistics market size is expected to reach USD 160.80 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 9.04% over the forecast period owing to the dominance of the U.S. in the pharmaceutical and biologics drugs market, the presence of a large number of players, and the rise in imports and exports of biopharmaceuticals.
High demand for COVID-19 vaccines in the country during the COVID-19 pandemic contributed to the hospitals, public organizations, and other institutions entering into partnerships with third-party logistics service providers. For instance, in 2020, the Ohio Department of Health partnered with Cardinal Health for the distribution of the COVID-19 vaccine. This is expected to have improved the demand for third-party logistics services in the country during the pandemic period.
There is a growing demand for biopharmaceuticals in the country for treating diseases such as cancer, autoimmune diseases, neurological diseases, and others. Furthermore, a significant number of researches are conducted in the country on drugs. All these factors are expected to boost the demand for third-party logistics services over the forecast period.
During the last five years, a significant number of pharmaceutical, biopharmaceutical, and medical devices were approved and launched in the country. For instance, in January 2023, Amgen launched Amjevita biosimilar for treating active polyarticular juvenile idiopathic arthritis. Similarly, in December 2022, the USFDA approved a drug named ublituximab-xiiy from Briumvi for treating multiple sclerosis. Similar drug approvals and drug launches in the country in the forecast period are expected to create opportunities for third-party logistics services in the U.S.
Furthermore, strategic initiatives undertaken by key entities in the market is expected to create growth opportunity for the regional market in the coming years. For instance, in January 2023, Censinet received funding of USD 9 million to accelerate third-party risk management in healthcare. This funding was led by the MemorialCare Innovation Fund including Ballad Ventures and Rex Health Ventures, bringing the Company's total funding to over USD 22 million.
U.S. Healthcare Third-party Logistics Market Highlights